Binder G, Grauer M L, Wehner A V, Wehner F, Ranke M B
Eur J Pediatr. 1997 Dec;156(12):905-10. doi: 10.1007/s004310050740.
In 135 women and 85 men who initially presented for tall stature, the outcome in treated (56 women and 33 men; cases) and untreated (controls) was investigated. At the time of height prediction, cases were significantly taller (P < or = 0.03) than the controls, they had higher target heights (P < 0.001) and adult height predictions (P < 0.001) (according to Bailey and Pinneau) compared to the controls. Bone age (according to Greulich and Pyle) and chronological age were well matched in both groups. Final height was measured after cessation of growth at a mean age above 21.5 years. The final height prediction according to Bailey and Pinneau (BP method) overestimated the final height in controls. The mean error of estimation was -0.14 cm (+/- 3.10) in women, and -1.86 cm (+/- 4.37) in men. Age at the time of prediction did not significantly correlate with the degree of the prediction error. Sex hormone therapy comprised a daily oral dose of 7.5 mg conjugated oestrogens in girls (plus 5 mg dydrogesterone for 10 days a month), while boys received 500 mg testosterone enantate, intramuscularly, every 2 weeks. Therapy was well tolerated. The mean corrected effect of height reducing therapy was 3.6 cm (range: 11.9 cm to -3.3 cm) in women and 4.4 cm (range: 14.2 cm to -5.2 cm) in men. Therapy was significantly more effective when started at an earlier chronological (P < 0.01) and bone age (P < 0.01). The residual mean growth, after therapy was stopped, was 1.8 (+/- 1.6) cm in women and 3.1 (+/- 2.3) cm in men. In men, post-treatment growth was inversely correlated to chronological age (P < 0.01) and bone age (P < 0.05) at the end of treatment, while these correlations were not significant in women. Both groups had a higher educational level than the normal population. Treated tall women reported teasing because of tallness more frequently than controls. In tall men, practical issues such as clothing size predominated. Maximum tolerated height in males was 200 cm and in females 180 cm, thus being nearly analogous to the actual professional criteria for treatment recommendation. A positive attitude to treatment was documented in over 90% of treated individuals.
Our results show that the BP method gives acceptable adult height predictions in girls, but less accurate predictions in boys. The treatment with high doses of sex hormones was low effective in both sexes and showed a wide range of response. For success, treatment must be initiated in early puberty and terminated late. The answers to a questionnaire revealed no major psychological or social maladjustment of treated individuals compared to those untreated.
在最初因身材高大前来就诊的135名女性和85名男性中,对接受治疗的患者(56名女性和33名男性;病例组)和未接受治疗的患者(对照组)的结果进行了调查。在进行身高预测时,病例组显著高于对照组(P≤0.03),与对照组相比,他们有更高的目标身高(P<0.001)和成人身高预测值(P<0.001)(根据贝利和皮诺方法)。两组的骨龄(根据格罗利希和派尔方法)和实际年龄匹配良好。在平均年龄超过21.5岁生长停止后测量最终身高。根据贝利和皮诺方法(BP法)的最终身高预测高估了对照组的最终身高。女性的平均估计误差为-0.14厘米(±3.10),男性为-1.86厘米(±4.37)。预测时的年龄与预测误差程度无显著相关性。女孩的性激素治疗为每日口服7.5毫克结合雌激素(每月加用5毫克地屈孕酮,共10天),而男孩每2周肌肉注射500毫克庚酸睾酮。治疗耐受性良好。身高降低治疗的平均校正效果在女性中为3.6厘米(范围:11.9厘米至-3.3厘米),在男性中为4.4厘米(范围:14.2厘米至-5.2厘米)。在实际年龄(P<0.01)和骨龄(P<0.01)较小时开始治疗,效果显著更佳。治疗停止后的残余平均生长在女性中为1.8(±1.6)厘米,在男性中为3.1(±2.3)厘米。在男性中,治疗后的生长与治疗结束时的实际年龄(P<0.01)和骨龄(P<0.05)呈负相关,而在女性中这些相关性不显著。两组的教育水平均高于正常人群。接受治疗的高个子女性因身高而被取笑的频率高于对照组。在高个子男性中,诸如服装尺寸等实际问题较为突出。男性的最大耐受身高为200厘米,女性为180厘米,这几乎与实际的治疗推荐专业标准类似。超过90%接受治疗的个体对治疗持积极态度。
我们的结果表明,BP法在女孩中能给出可接受的成人身高预测,但在男孩中预测准确性较低。高剂量性激素治疗在两性中效果均较低,且反应范围较广。为取得成功,治疗必须在青春期早期开始并在晚期结束。问卷调查的答案显示,与未接受治疗的个体相比,接受治疗的个体没有重大的心理或社会适应不良。